Advanced Catheter Therapies

Advanced Catheter Therapies, Inc. (ACT) is an early stage research and development medical device company with a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

ACT has initially focused its resources on the problem of restenosis and is developing the game-changing Occlusion Perfusion Catheter™ (OPC™). The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature.

Also in the development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).


Advanced Catheter Therapies’ OPC Device Featured in Live Case at NCVH
CHATTANOOGA, June 23, 2015 – The Occlusion Perfusion Catheter™ (OPC), a FDA-approved multi-lumen balloon catheter providing targeted intravascular drug delivery, was featured in a live case presentation during the 16th Annual New Cardiovascular Horizons (NCVH) Conference. Frank T. Bunch, M.D., F.A.C.C., principal investigator for the COPPER-A clinical trial, performed the case, which can be viewed on the NCVH website at 1:50 PM. Dr. Bunch also made a presentation on the science behind the OPC at the conference.

Rex Teeslink, M.D., the device’s inventor, NCVH faculty member, and scientific advisor for Advanced Catheter Therapies, Inc. (ACT), was present for the live case, something that both he and Dr. Bunch pointed to as a milestone for the device. “It was very exciting to be part of a live case,” said Dr. Teeslink. “It shows attendees that science is progressing beyond drug coated balloons. We believe the OPC represents the next generation of drug delivery devices.”

Read more